This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.
We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.
“I am pleased to report strong progress by Sensyne Health in our first reporting period as a public company, achieving a number of important milestones.
Our business development pipeline is showing good momentum and is on track to meet the objectives set out at our Initial Public Offering (“IPO”). The Company is in an excellent position to capitalise on the data assets and Clinical Artificial Intelligence capabilities provided by its equity partnerships with NHS Trusts and the University of Oxford in order to meet the growing world-wide demand for data-driven healthcare innovation.”
Click here to view full interim results.
Analyst and Investor briefing
Lord Drayson, Chief Executive Officer, and Lorimer Headley, Chief Financial Officer, will present the Interim Results for analysts and investors today at 10.30am GMT. There will be a simultaneous live conference call.
Dial-in detail are:
Participant local dial-in: +44 (0) 203 0095710
Participant free phone dial-in: 08003767425
Participant US free phone dial-in: +18668692321
Participant code: 6992215
A live webcast of the meeting and the presentation slides, will be available on the investor section of Sensyne Health’s website:
https://www.sensynehealth.com/investors/investor-hub
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
Lord (Paul) Drayson PhD FREng, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Julia Wilson, Director of Investor Relations
Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information, please visit: www.sensynehealth.com
“I am pleased to report strong progress by Sensyne Health in our first reporting period as a public company, achieving a number of important milestones.
Our business development pipeline is showing good momentum and is on track to meet the objectives set out at our Initial Public Offering (“IPO”). The Company is in an excellent position to capitalise on the data assets and Clinical Artificial Intelligence capabilities provided by its equity partnerships with NHS Trusts and the University of Oxford in order to meet the growing world-wide demand for data-driven healthcare innovation.”
Click here to view full interim results.
Analyst and Investor briefing
Lord Drayson, Chief Executive Officer, and Lorimer Headley, Chief Financial Officer, will present the Interim Results for analysts and investors today at 10.30am GMT. There will be a simultaneous live conference call.
Dial-in detail are:
Participant local dial-in: +44 (0) 203 0095710
Participant free phone dial-in: 08003767425
Participant US free phone dial-in: +18668692321
Participant code: 6992215
A live webcast of the meeting and the presentation slides, will be available on the investor section of Sensyne Health’s website:
https://www.sensynehealth.com/investors/investor-hub
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
Lord (Paul) Drayson PhD FREng, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Julia Wilson, Director of Investor Relations
Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information, please visit: www.sensynehealth.com
“I am pleased to report strong progress by Sensyne Health in our first reporting period as a public company, achieving a number of important milestones.
Our business development pipeline is showing good momentum and is on track to meet the objectives set out at our Initial Public Offering (“IPO”). The Company is in an excellent position to capitalise on the data assets and Clinical Artificial Intelligence capabilities provided by its equity partnerships with NHS Trusts and the University of Oxford in order to meet the growing world-wide demand for data-driven healthcare innovation.”
Click here to view full interim results.
Analyst and Investor briefing
Lord Drayson, Chief Executive Officer, and Lorimer Headley, Chief Financial Officer, will present the Interim Results for analysts and investors today at 10.30am GMT. There will be a simultaneous live conference call.
Dial-in detail are:
Participant local dial-in: +44 (0) 203 0095710
Participant free phone dial-in: 08003767425
Participant US free phone dial-in: +18668692321
Participant code: 6992215
A live webcast of the meeting and the presentation slides, will be available on the investor section of Sensyne Health’s website:
https://www.sensynehealth.com/investors/investor-hub
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
Lord (Paul) Drayson PhD FREng, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Julia Wilson, Director of Investor Relations
Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information, please visit: www.sensynehealth.com
“I am pleased to report strong progress by Sensyne Health in our first reporting period as a public company, achieving a number of important milestones.
Our business development pipeline is showing good momentum and is on track to meet the objectives set out at our Initial Public Offering (“IPO”). The Company is in an excellent position to capitalise on the data assets and Clinical Artificial Intelligence capabilities provided by its equity partnerships with NHS Trusts and the University of Oxford in order to meet the growing world-wide demand for data-driven healthcare innovation.”
Click here to view full interim results.
Analyst and Investor briefing
Lord Drayson, Chief Executive Officer, and Lorimer Headley, Chief Financial Officer, will present the Interim Results for analysts and investors today at 10.30am GMT. There will be a simultaneous live conference call.
Dial-in detail are:
Participant local dial-in: +44 (0) 203 0095710
Participant free phone dial-in: 08003767425
Participant US free phone dial-in: +18668692321
Participant code: 6992215
A live webcast of the meeting and the presentation slides, will be available on the investor section of Sensyne Health’s website:
https://www.sensynehealth.com/investors/investor-hub
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
Lord (Paul) Drayson PhD FREng, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Julia Wilson, Director of Investor Relations
Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information, please visit: www.sensynehealth.com
“I am pleased to report strong progress by Sensyne Health in our first reporting period as a public company, achieving a number of important milestones.
Our business development pipeline is showing good momentum and is on track to meet the objectives set out at our Initial Public Offering (“IPO”). The Company is in an excellent position to capitalise on the data assets and Clinical Artificial Intelligence capabilities provided by its equity partnerships with NHS Trusts and the University of Oxford in order to meet the growing world-wide demand for data-driven healthcare innovation.”
Click here to view full interim results.
Analyst and Investor briefing
Lord Drayson, Chief Executive Officer, and Lorimer Headley, Chief Financial Officer, will present the Interim Results for analysts and investors today at 10.30am GMT. There will be a simultaneous live conference call.
Dial-in detail are:
Participant local dial-in: +44 (0) 203 0095710
Participant free phone dial-in: 08003767425
Participant US free phone dial-in: +18668692321
Participant code: 6992215
A live webcast of the meeting and the presentation slides, will be available on the investor section of Sensyne Health’s website:
https://www.sensynehealth.com/investors/investor-hub
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
Lord (Paul) Drayson PhD FREng, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Julia Wilson, Director of Investor Relations
Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information, please visit: www.sensynehealth.com